Skip to main content

 

The Biosafety Advisory Council (BAC) is one of the two pillars (with the Service Biosafety and Biotechnology - SBB) of the scientific evaluation system that has been set up in Belgium to advise the Federal and Regional competent authorities about the biosafety of activities involving genetically modified organisms (GMOs) and/or pathogens.
 
The Council is composed of 12 effective and 12 substitute members designated by the different Regional and Federal competent authorities. It is assisted in its scientific work by external experts from academic institutions and by the SBB. The secretariat of the Council is ensured by the SBB.


The Council advises the authorities for all regulatory dossiers related to the deliberate release of GMOs in the environment or the placing on the market of GMOs and GMO-based products. The Council can be consulted by the Regions for contained activities involving GMOs and/or pathogens (i.e. activities taking place in laboratories, greenhouses, animal husbandries, production plants or hospital rooms).

Latest news

Advice on application EFSA-GMFF-2022-5890 (maize MON 95275) from Bayer intended for import and processing, food and feed
Advice on application EFSA-GMO-NL-2022-174 (maize DP910521) from Corteva Agriscience intended for import and processing, food and feed
Advice on application EFSA-GMFF-2022-3670 (RX-029, genetically modified maize MON 89034 x 1507 x NK603) from Bayer CropScience and Corteva Agriscience intended for import and processing, food and feed
Advice on application EFSA-GMFF-2022-9170 (RX-027, genetically modified maize MON 89034 x 1507 x MON 88017 x 59122) from Bayer CropScience and Corteva Agriscience intended for import and processing, food and feed
Advice on application EFSA-GMFF-2022-10651 (genetically modified maize MON 94804) from Bayer intended for import and processing, food and feed
Advice on dossier B/BE/24/BVW5: Phase 3 clinical trial (Pfizer) involving a GM anadeno-associated viral vector for treatment of hemophilia B
Advice on dossier B/BE/24/BVW4: Phase 3 clinical trial (Sarepta Therapeutics) involving a GM non-replicating adeno-associated viral vector for gene therapy
Advice on dossier B/BE/23/BVW3: Phase 1 clinical trial (AstriVax) involving a GM live attenuated yellow fever virus for vaccination
Advice on application EFSA-GMO-NL-2019-159 (genetically modified maize DP202216) from Pioneer intended for import and processing, food and feed
Advice on dossier B/BE/24/V2: Field trial (VIB) involving GM poplars with a modified wood composition